BCRX

#1850
BioCryst Pharmaceuticals Inc
9.54 USD
-1.34%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
9.51
9.56
Faixa anual
6.00
11.31
Mudança diária
-1.34%
Mudança mensal
+16.06%
Mudança em 6 meses
+38.86%
Mudança anual
+28.92%
Fechamento anterior
9.67
Abrir
9.55
Bid
Ask
Mínimo
9.51
High
9.56
Volume
224
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 2.39 B
  • Employee 435
  • Founded 1986
  • CEO Jon P. Stonehouse
  • Website www.biocryst.com
  • Headquarter Delaware, United States
  • FIGI BBG000BLYWX6
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
6.45
Price to sales ratio
1.95

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Notícias